Press Releases April 28, 2025: MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity…MaaT PharmaApril 28, 2025
Press Releases April 14, 2025: Availability of MaaT Pharma’s 2024 Universal Registration Document (URD) Availability of MaaT Pharma’s 2024 Universal Registration Document (URD) Lyon, France, April 14, 2025 -…MaaT PharmaApril 14, 2025
Press Releases April 8, 2025: MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033…MaaT PharmaApril 8, 2025
Press Releases April 7, 2025: MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co Lyon,…MaaT PharmaApril 7, 2025
Press Releases April 4, 2025: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…MaaT PharmaApril 4, 2025
Press Releases March 31, 2025: MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve…MaaT PharmaMarch 31, 2025
Press Releases March 27, 2025: MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024…MaaT PharmaMarch 27, 2025
Press Releases March 18, 2025: MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial…MaaT PharmaMarch 18, 2025
Press Releases March 11, 2025: MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013 MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for…MaaT PharmaMarch 11, 2025
Press Releases January 21, 2025: MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033…MaaT PharmaJanuary 21, 2025